| Document |
Document Title |
|
WO/2003/035609A1 |
Zwitterionic imide compounds are provided according to the formula: R1-SO2-N--SO2-R2+, where R1 and R2+ are any suitable groups. Typically R1 is a highly fluorinated alkane and R2+ contains a quaternary ammonium group or a heteroatomic a...
|
|
WO/2003/032993A1 |
The invention relates to the use of Phosphodiesterase IV inhibitors and/or the physiologically acceptable salts thereof in the production of a medicament for the treatment of osteoporosis, tumors, tumor metastases, atherosclerosis, rheum...
|
|
WO/2003/033484A1 |
The invention relates to substituted piperazine cyclohexane carboxylic acid amides of formula (I), methods for the production and use thereof in medicaments, especially for the prophylaxis and/or the treatment of cardiovascular diseases.
|
|
WO/2003/029211A1 |
A difluoroalkene derivative which is sufficiently effective in controlling various pests even when used in a small dose and is highly safe for crops, natural enemies to the pests, and animals&semi and an intermediate for the derivative. ...
|
|
WO/2003/028729A2 |
The present invention relates to prodrug compounds, comprising a 5- or 6- membered heterocyclic or aromatic ring substituted with a derivatized amidine, as well as compositions and methods useful for preventing and treating thrombotic co...
|
|
WO/2003/029216A1 |
The present invention relates to compounds, and prodrugs thereof, compositions and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inh...
|
|
WO/2003/029224A1 |
The present invention relates to compounds, and prodrugs thereof, composition and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inhi...
|
|
WO/2003/027097A1 |
The invention relates to new substituted alkylaminopyridazinone derivatives of the general Formula (I), (wherein R¿1? is hydrogen or alkyl having 1-4 carbon atoms; one of X and Y stands for hydrogen or halogen and the other represents a...
|
|
WO/2003/027077A1 |
Compounds represented by the following general formula (1), which have an effect of inhibiting IL−β production, are highly soluble in water and have a favorable oral absorbability, and medicinal compositions containing the same: (1) w...
|
|
WO/2003/027078A1 |
New substituted alkylaminopyridazinone derivatives of the general Formula (I), (wherein R¿1? is hydrogen or alkyl having 1-4 carbon atoms; X is hydrogen or halogen; R¿2? is hydrogen or alkyl having 1-4 carbon atoms; n is 1, 2 or 3; Q a...
|
|
WO/2003/024938A1 |
The invention relates to compounds of formula (I), wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿ and R?6¿ have the meaning cited in the description, several methods for the production thereof and the use thereof in order to combat undesirab...
|
|
WO/2003/024441A1 |
A medicinal composition which exasperates apo AI expression as a remedy for circulatory diseases based on the HDL function enhancement. It is an apo AI expression accelerator which contains a compound represented by the formula (I), a pr...
|
|
WO/2003/017765A1 |
Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.
|
|
WO/2003/018563A1 |
A novel class of pyridazine compositions and related methods of use.
|
|
WO/2003/015774A1 |
The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R?1¿, R?2¿, R?3¿, n and m are as described in the specification, in the preparation of a medicament for the treatment or prev...
|
|
WO/2003/015785A1 |
The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present in...
|
|
WO/2003/016286A1 |
A compound represented by the general formula (I) (wherein R1 is hydrogen, halogeno, alkyl, etc.&semi R2 is hydrogen, halogeno, alkyl, etc.&semi R3, R4, R5, R6, and R7 each independently is hydrogen, halogeno, optionally substituted alky...
|
|
WO/2003/014090A1 |
Compounds which are amino-phthalazinone derivatives according to formula 1 and pharmaceutically acceptable salts thereof, togetherwith pharmaceutical compositions comprising them are disclosed; these compounds or compostions are useful i...
|
|
WO/2003/013484A2 |
Compounds of formula (I), in which X independently from each other denotes a CH group or a nitrogen atom and R represents an optionally substituted five or six membered nonaromatic carbocyclic ring or an nonaromatic or aromatic heterocyc...
|
|
WO2002068399B1 |
The invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, the invention relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in th...
|
|
WO/2003/010150A1 |
The invention relates to the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylam
ino]-propylamino]-3-[2H]-pyridazinone fumarate, a process for the preparation thereof, pharmaceutical compositions containin...
|
|
WO/2003/010153A1 |
The present invention provides novel N-alkyl-N-phenylhydroxylamine derivatives containing metal chelating groups, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various med...
|
|
WO/2003/006454A2 |
Compounds of general formula (I), in which Het represents a five or six membered saturated, partially unsaturated or aromatic ring containing between one and six heteroatoms of the group N, O, S, in which the heterocycle is substituted i...
|
|
WO/2003/006023A1 |
aP2 inhibiting compounds are provided having the formula [I] wherein A, X, R and Z are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitors ...
|
|
WO/2003/006423A1 |
Disclosed are compounds of the formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzeheimer's disease and ot...
|
|
WO/2003/004035A1 |
A method for reducing mortality in a mammal with congestive heart failure,comprising administering to said mammal an effective amount of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl
]acetamide, particularly its (R)-enanti...
|
|
WO/2003/004474A1 |
Compounds of formula (I), wherein A¿1? and A¿2? are each independently of the other unsubstituted or mono- to penta-substituted aryl or unsubstituted or, depending upon the possibility of substitution at the ring, mono- to tetra-substi...
|
|
WO/2003/002541A1 |
The invention relates to novel compounds, to a method for the production of said compounds and to the use thereof as medicaments, more particularly as antiviral agents, especially against cytomegalovirus.
|
|
WO/2002/098849A2 |
Disclosed are compounds of formula X, where R¿n?, R¿20?, R¿1?, R¿2?, R¿3?, and R¿c? are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising c...
|
|
WO/2002/096516A1 |
A method is provided for the prevention or inhibition of cardiovascular disease comprising the admiministration of a cyclooxygenase-2 selective inhibitor with a dose of radiation.
|
|
WO/2002/092087A1 |
The present invention relates to inhibitors of P38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The inven...
|
|
WO/2002/090333A1 |
The present invention relates to a compound of formula (1), (2) or (3) having the following structures: Formula 1, 2, 3 wherein X, Y, and Z are independently C or N; A is a direct bond, CH2 or NH;B is a direct bond or NH; n&equals 0-2; R...
|
|
WO/2002/087584A1 |
This invention relates to pharmaceutical compositions and kits comprising pyridazinone compounds and cyclooxygenase-2 inhibitors, therapeutic methods of treatment or prevention of certain complications arising from diabetes mellitus in m...
|
|
WO/2002/085838A1 |
The present invention relaters to copper-catalyzed carbon-heteroatom and carbon-carbon bond-forming methods. In certain embodiments, the present invention relates to copper-catalyzed methods of forming a carbon-nitrogen bond between the ...
|
|
WO/2002/085885A1 |
The compounds of formula I, in which R1, R2, R3, A, X, s and R9 have the meanings as given in the description are novel effective PDE4 inhibitors.
|
|
WO/2002/085906A2 |
The compounds of formula (I) in which R1, R2, R3, R4 and R5 have the meanings as given in the description are PDE4/7 inhibitors.
|
|
WO/2002/080912A1 |
A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically ef...
|
|
WO/2002/078625A2 |
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation -related condition in a subject in need of such treatment or prevention. One therapeutic com...
|
|
WO/2002/078626A2 |
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic comb...
|
|
WO/2002/074267A1 |
The invention relates to a novel composition that is used for the oxidation dyeing of keratin fibres, in particular human hair, comprising at least one particular hydrazone-type compound as an oxidation base and at least one coupling age...
|
|
WO/2002/072099A1 |
A therapeutic and/or preventive agent for diabetic ischemic heart disease, characterized in that it comprises, as an active component, a phenylpyridazinone derivative represented by the following general formula (1) or (2): (1) (2) where...
|
|
WO/2002/070471A1 |
Compounds of the formula (I) in which R?1¿ is CN, or C(=NH)-NH¿2?, CON(R?3¿)¿2? or [C(R?4¿)¿2?]¿n?N(R?3¿)¿2?, each of which is unsubstituted or monosubstituted by C(=O)R?3¿, COOR?3¿, or?3¿ or by a conventional amino-protectin...
|
|
WO/2002/068367A1 |
The present invention generally relates to methods of inhibiting ethylene responses in plants and plant materials, and particularly relates to methods of inhibiting various ethylene responses including plant maturation and degradation, b...
|
|
WO/2002/066431A1 |
The invention relates to substituted heterocyclo-norbornylamine derivatives of formula (I) with nitrogen in the exo position and a five-membered ring annealed in the endo position, or the derivatives of formula (Ia) with nitrogen in the ...
|
|
WO/2002/066437A1 |
The invention relates to novel quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
|
|
WO/2002/064545A1 |
The present invention relates to acylated indanyl amines according to the general formula (I) where R?1¿-R?4¿ have the meanings given in the description, A is CH¿2? CHOH or CH-(C¿1?-C¿3?-alkyl), B is CH¿2? or CH-(C¿1?-C¿3?-alkyl)...
|
|
WO/2002/064546A2 |
The present invention relates to compounds according to the general formula (I) wherein R?I¿-R?4¿ have the meanings given in the description, A is CH¿2?, CHOH or CH(C¿1?C¿3?-alkyl) B, C and D are independently CH¿2? or CH-(C¿1?-CÂ...
|
|
WO/2002/064584A1 |
The compounds of a formula I, in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors.
|
|
WO/2002/060858A1 |
A compound having strong inhibitory activity against the Maillard reaction; a medicine for use in the prevention of or treatments for diseases in which the Maillard reaction participates; and an additive for preventing the deterioration ...
|
|
WO/2002/057236A1 |
Novel compounds of the formula I in which W, X, Y, T, R?1¿ and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.
|
